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Mycobacterium tuberculosis mtFabD is an essential malonyl-CoA:AcpM transacylase and is important for vital protein-protein
interactions within type 2 fatty acid synthase FASII. mtFabD contacts KasA, KasB, FabH, InhA, and possibly also HadAB, HadBC,
and FabG1/MabA. Disruption of mtFabD’s interactions during FASII has been proposed for drug development. Here, the gene
for a mitochondrially targeted mtFabD was ectopically expressed in Saccharomyces cerevisiae mct1Δ mutant cells lacking the
corresponding mitochondrial malonyl-CoA transferase Mct1p, allowing the mutants to recover their abilities to respire on glycerol
and synthesize lipoic acid. Hence, mtFabD could physiologically function in an environment lacking holo-AcpM or other native
interaction partners.
Copyright © 2009 Aner Gurvitz.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
A new approach for eradicating tuberculosis has been
proposed that centers on perturbing vital protein-protein
interactions associated with the essential mycobacterial
process of type 2 fatty acid synthase, FASII [1]. FASII is
dedicated to the production of mycolic acids and is targeted
by isoniazid, which represents only one of less than a handful
of veteran ﬁrst-line drugs for combating Mycobacterium
tuberculosis. Mycolic acids are very long chain α-branched
β-hydroxylated fatty acids that help form the pathogen’s
defensive layer [2].
A critical step in mycobacterial FASII is represented
by the transfer of the malonyl moiety from coenzyme A
(CoA) to acyl carrier protein (activated holo-AcpM), which
is eﬀected by a malonyl-CoA:AcpM transacylase mtFabD
(Rv2243), so as to generate malonyl-AcpM [3]. Importantly,
mtFabD also plays a key role in holding together FASII
enzymes within a protein complex [1]. The structure of
this complex is presumed to occur as a constellation of a
core triad, with each one of the three identical core units
independently contacting a single condensing enzyme, KasA,
KasB, or FabH. KasB is further linked to Pks13 responsible
for subsequent maturation of the nascent mycolic acid,
and both KasA and KasB provide condensing activities for
additional methyltransferases during this process [1].
The FASII core unit [1] is thought to be composed
of mtFabD, FabG1/MabA (representing 3-oxoacyl-AcpM
reductase), InhA (2-trans-enoyl-AcpM reductase), and 3-
hydroxyacyl-AcpM dehydratase, ostensibly HadAB and
HadBC [4]. Within this core, mtFabD occurs in close
proximity to—and also forms speciﬁc protein-protein inter-
actions with—itself, InhA, and possibly also with HadAB
and HadBC. In addition, it can also be directed to contact
mutant versions of nondimerizing FabG1/MabA [1]. It
was proposed that disrupting mtFabD interactions may be
detrimental for mycobacterial survival, and this should be
considered as a possible new approach in the search for novel
antituberculous drugs [1]. Hence, it would be important to
study mtFabD function in a situation where these formal
protein-protein interactions are altered or nonexistent, such
as in yeast mitochondrial FASII.
The fungal FASII equivalent of mtFabD is exempliﬁed
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Figure 1: Comparison of M. tuberculosis mtFabD with its E. coli and S. cerevisiae homologs. Multalin- and Genedoc-based comparison of
the deduced amino acid sequence of M. tuberculosis FabD (Rv2243), E. coli FabD (AP 001718), and S. cerevisiae Mct1p (Yor221cp). Dashes
indicate the arrangement of the sequences for best ﬁt. Black shadings refer to conserved amino acid residues among all three sequences
whereas the darker and lighter grey shadings denote regions with more relaxed residue similarities not necessarily shared by the full set of
sequences.
more distant to the mycobacterial protein than is Escherichia
coli FabD (Figure 1), whose latter temperature-dependent
inactivation can be compensated for by ectopically express-
ing mtFabD [3]. Yeast mutant cells devoid of Mct1p
contain underdeveloped mitochondria, fail to respire or
produce suﬃcient levels of lipoic acid, and are exclusively
fermentative [5]. Here, mutant yeast cells expressing a
mitochondrially targeted form of mycobacterial mtFabD
were compared to an otherwise isogenic wild-type strain
for growth, respiration, and lipoic acid production, and the
implications are discussed.
2.MaterialsandMethods
The fabD sequence was ampliﬁed from H37Rv genomic
DNA by thermocycling using oligonucleotides MLS-FabD F
5 -TTATCCATGGTTGCGTTGCTCGCACCCGGAC-3  and
FabD R 5 -TATTAAGCTTATAGGTTTGCCAGCTCGTCC-
3  that introduced 5 NcoIa n d3  HindIII sites. The ampliﬁed
fabD DNA was processed in such a way that it was preceded
by the nucleotides for the Coq3p [6] mitochondrial leader
sequence (MLS), and the gene fusion was ligated behind
the CTA1 promoter, as described [7]. The ﬁnal mtFabD
expression plasmid, referred to as pYE352:CTA1-COQ3-
FABD, was based on a URA3-marked YEp352 multicopy
plasmid [8]. A control URA3-marked multicopy plasmid
vector YEplac195 [9] was used to transform the wild type
or the otherwise isogenic mutant to uracil prototrophy.
Nucleotide sequencing of the fabD insert veriﬁed that no
mutations were introduced during the ampliﬁcation process
and that the COQ3-fabD junction remained intact.
The wild-type yeast strain BY4741 (MATa his3Δ1
leu2Δ0m e t 1 5 Δ0u r a 3 Δ0) and its mct1Δ derivative (yor221c::
kanMX) were obtained from EUROSCARF (http://www
.uni-frankfurt.de/). Transformation of yeast strains
was performed using a published method [10], and
transformants were selected on solid synthetic deﬁned-
glucose medium lacking uracil (SD-Ura) that consisted of
0.67% (wt/vol) yeast nitrogen base without amino acids,
2% (wt/vol) D-glucose, and 3% (wt/vol) agar, with all
supplements added except for uracil (Sigma-Aldrich Inc.
St. Louis, MO). Synthetic complete glycerol medium
(SCglycerol) was made up essentially as above, but with
the addition of uracil and the replacement of glucose
with 3% (wt/vol) glycerol as the sole carbon source.
Other standard yeast [11]a n dE. coli [12] media used
are described. Respiration competence was assayed by
overlaying cells grown on solid SD-Ura medium with
0.1% (wt/vol) 2,3,5-triphenyltetrazolium chloride (TTC)
in 0.067 M phosphate-buﬀered saline and 1.5% (wt/vol)
low-melting temperature agarose [13]. Lipoic acid content
of yeast strains was monitored by a biological assay described
previously [14, 15] using the lipoic acid deﬁcient E.
coli strain JRG33. Multalin (http://npsa-pbil.ibcp.fr/cgi-
bin/npsa automat.pl?page=/NPSA/npsa multalin.html)a n d
Genedoc (http://www.nrbsc.org/gfx/genedoc/index.html)
were accessed to construct the amino acid alignment in
Figure 1.
3. Results
To examine whether mtFabD would be able to act as a
physiological malonyl-CoA transferase in S. cerevisiae, the
correspondinggenewasexpressedinyeastmct1Δcellsdevoid
of the native mitochondrial malonyl-CoA:Acp1p transferase
Mct1p. The mycobacterial protein was generated as a hybrid
construct that was preceded by the yeast Coq3p MLS
capable of directing proteins to the mitochondria [6]. As
controls, mct1Δ cells and the corresponding wild type were
transformedwithaURA3-markedYEplac195plasmidvector
[9]. Thereafter, the three strains were propagated overnight
on SD-Ura glucose medium selecting for plasmid presence.
Following tenfold serial dilution, cultures were spotted onto
solid SD-Ura or SCglycerol media, and the plates were
incubated at 30
◦C until single colonies were detectable.
The results demonstrated that mct1Δ mutants expressing
mtFabD resembled to an extent the wild-type strain in that
they were capable of some growth on glycerol as the soleComparative and Functional Genomics 3
carbon source (Figure 2a). As anticipated, those mutant cells
harboring a URA3-marked plasmid vector that was devoid
o fas e q u e n c ef o rt r a n s f e r a s ea c t i v i t yw e r en o ta b l et og r o w
or divide on this medium, albeit they demonstrated ample
fermentative growth on glucose (Figure 2b). To investigate
whetherthegrowthobservedformtFabD-expressingmutant
cells correlated with a regenerated electron transfer chain,
2,4,5-triphenyltetrazolium chloride (TTC) was applied to
the previous SD-Ura plate. The results demonstrated that
mutant mct1Δ cells expressing mtFabD were similar to the
wild type in that they generated the red chromophore
(Figure 2c). Hence, mtFabD eﬀected the recuperation of the
electron transfer chain in mutant mct1Δ cells, which enabled
them to resume respiratory growth on a nonfermentable
carbon source.
Finally, to place mtFabD action within the context of
fatty acid biosynthesis in yeast mitochondria, lipoic acid
production was examined in the three strains. In this test,
lipoic acid was prepared from triplicate yeast cultures grown
on SD-Ura, and the extracts were used to supplement
a synthetic growth medium into which were inoculated
auxotrophic bacterial cells. The values were calculated based
on a standard curve that plotted bacterial growths versus
known amounts of lipoic acid that had been added to
the otherwise restrictive medium. The results showed that
extracts derived from the wild-type strain led to a level of
bacterial growth that was equivalent to 208 ± 67ng lipoic
acid per gram wet weight of yeast cells (values are mean ±
S.D., n = 3), whereas those derived from mct1Δ mutant
cells harboring the plasmid vector supported only a nominal
growth commensurate with 20ng lipoic acid per gram wet
weight. Importantly, extracts from mutant cells expressing
mtFabD yielded near wild-type bacterial growth levels of 184
± 37ng lipoic acid per gram wet weight. Taken together,
ectopically expressed mtFabD could compensate for the
loss of fungal Mct1p, and the signiﬁcance of this result is
discussed.
4. Discussion
Mycobacterium tuberculosis causes widespread human death
and immense suﬀering, and it is estimated that about 2
million people die annually from tuberculosis. No less than
one third of humanity is thought to be burdened with
M. tuberculosis, which kills more adults than any other
disease due to a single infectious agent [2]. Numerous
tuberculosis patients are now infected with resistant strains,
and so the development of novel therapeutics against M.
tuberculosis is a pressing issue. Recently, a new approach for
battling tuberculosis has been proposed, in which mtFabD-
dependent protein-protein interactions considered pivotal
for the production of mycolic acids by FASII are to be singled
out for perturbance [1].
In this study, M. tuberculosis fabD was shown to be
interchangeable with the S. cerevisiae gene for Mct1p during
respiratory growth and de novo lipoic acid biosynthesis.
The chemistry underlying the present phenotype rescue of
a yeast FASII mutant is fundamentally diﬀerent compared
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Figure 2: Respiratory growth of S. cerevisiae mct1Δ mutant
cells expressing M. tuberculosis mtFabD. Wild-type yeast cells
harboring a YEplac195 plasmid vector and mct1Δ cells similarly
transformed to uracil prototrophy or expressing mitochondrially
targeted Rv2243 (mtFabD) from a YEp352 plasmid (both plasmid
types are marked with URA3) were grown on SD-Ura medium
that selected for plasmid presence, and following serial dilution
(triangle), were applied to solid media that consisted of (a) 3%
(wt/vol) glycerol (SCglycerol) or (b) 2% (wt/vol) glucose (SD-Ura).
The plates were incubated at 30
◦C until single colonies appeared,
and recorded photographically. For (c), following an additional 4 d
incubation, the SD-Ura plate was overlaid with 0.1% (wt/vol) 2,4,5-
triphenyltetrazolium chloride (TTC), and the development of the
red chromophore was monitored.
to previous demonstrations of physiological function within
thiscontext,forexample,usingInhA[7],HadABandHadBC
[16], or FabG1/MabA and FabG4 [17]. This diﬀerence
lies in the fact that here mtFabD modiﬁed the thioester
bond to the 4 -phosphopantetheine group of yeast acyl
carrierproteinAcp1p,whereasthepreviouslytestedenzymes
acted on Acp1p’s cargo acyl group. There are a number
of surprises associated with the present ﬁnding. One, yeast
cells were capable of metabolizing very GC-rich genetic4 Comparative and Functional Genomics
information (67.3% for fabD compared with only 37.6% for
MCT1) and were successful in expressing a mitochondrially
targeted heterologous protein that could fold into its native
conformation in a wholly nonmycobacterial environment.
Two, despite mtFabD’s marked preference for mycobacterial
AcpM over bacterial ACP [3], it nevertheless tolerated
the evolutionarily more distant yeast Acp1p. And three,
although mtFabD interacts within its native environment
with additional FASII enzymes [1, 18], the mycobacterial
transacylase was still functional in the absence of these
interaction partners.
It should be underscored that the existence per se of
an FASII complex in mycobacteria is not disputed as a
result of this study, nor are the contacts made by mtFabD
with its partners. Nevertheless, the recent demonstration of
FabG1/MabA function in fungi [17] has put into question
the extent to which protein contacts are really important for
mycobacterial FASII [18]. The present ﬁnding that mtFabD
can also work in yeast should therefore raise the alarm for
those subscribing to the point of view that disrupting FASII-
dependentassociationswouldbelethaltoM.tuberculosisand
perhaps dampen some of their expectations that compounds
capable of annulling these contacts would have pharmaco-
logicaluses.Theworkoutlinedhereadditionallyunderscores
theversatilityofthisfungalsystemforexploringthefunction
of pathogen proteins in complete quarantine from their
native metabolic networks.
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